← Leaderboards
Sunita Desai
New York University School Of Medicine
$1,938,672
Attributed
$2,275,785
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,489,478 · 2
AHRQ$786,307 · 1
By mechanism
R01$1,489,478 · 2
K01$786,307 · 1
Top collaborators
- John Kent Lin1 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Magdalena Cerda$12,869,413
- Silvia Saboia Martins$12,198,031
- Babak Tofighi$3,327,712
- Keng-Yen Huang$4,429,307
- Janet Nakigudde$2,438,917
Others in their field
Other Emerging Leaders on “Patient-Focused Outcomes”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$49,703,204
- Xinhua Li · Nano Terra, Inc.$36,065,022
- Jennifer Marie Suga · Kaiser Foundation Research Institute$29,218,159
- Pamela Winer Goldberg · Medical Device Innovation Consortium$28,780,000
- Olwen Hahn · Brigham And Women'S Hospital$23,691,312
- Tareq Al Baghdadi · Saint Joseph Mercy Health System$16,009,505
Research focus
Patient-Focused OutcomesLinkHealth EquityOutpatientsProgramsCaringEthnic OriginHealth Care DisparityIncentivesMedication CompliancePoliciesPolicy MakerQuasi-ExperimentServicesDisadvantagedDisparityHealth CareContractsHospitalsImproved OutcomeInvestmentsClinics And HospitalsChronic Myeloid LeukemiaAnalytical Method
Grant awards (7)
Medicaid Delivery System Reform Incentive Payment (DSRIP) Programs: Impacts on Health Care Use, Coordination, Outcomes, and Disparities among Patients with Mental Illness$815,251
R01 · FY2025 · MH · contact PI
Impact of the 340B Drug Pricing Program on Medication Utilization, Health Outcomes, and Disparities in Medicare$674,227
R01 · FY2025 · AG · contact PI
Designing policies to incentivize high-quality health care for vulnerable Americans: Evidence from the 340B Drug Pricing Program$157,442
K01 · FY2024 · HS · contact PI
Designing policies to incentivize high-quality health care for vulnerable Americans: Evidence from the 340B Drug Pricing Program$156,082
K01 · FY2023 · HS · contact PI
Designing policies to incentivize high-quality health care for vulnerable Americans: Evidence from the 340B Drug Pricing Program$157,637
K01 · FY2022 · HS · contact PI
Designing policies to incentivize high-quality health care for vulnerable Americans: Evidence from the 340B Drug Pricing Program$157,722
K01 · FY2021 · HS · contact PI
Designing policies to incentivize high-quality health care for vulnerable Americans: Evidence from the 340B Drug Pricing Program$157,424
K01 · FY2020 · HS · contact PI